The overall objective of the Tissue Procurement Facility (TPF) Shared Resource is to procure and provide needed tissue specimens to Stanford Cancer Center investigators to support their cancer-related research. TPF activities and services include collecting and banking freshly frozen tumor and normal tissue from excess surgical material and from autopsy, providing fresh tumor tissue for viable cell studies, processing and banking blood specimens (plasma, serum, leukocyte DNA) from cancer patients, maintaining a tissue database with links to clinicopathological data, providing histological staining and pathological review and coordinating patient consent and ensuring regulatory compliance. As a centralized shared resource, the TPF adds value through experience, efficiency, standardization, accountability, protection of patient confidentially and timely completion of research. An oversight committee provides recommendations on facility policies and activities, and performs scientific and logistical review of service requests. Though largely supported by the Cancer Center and the School of Medicine, operating costs are defrayed by modest user fees. In the past 12 months alone, the TPF has provided over 450 fresh and frozen tissue specimens to 25 Cancer Center investigators from eight Cancer Center programs, to support cutting-edge cancer research in diverse areas, including cancer genomics, cancer stem cells and molecular imaging. The TPF also provides a portal to a """"""""virtual bank"""""""" linking inventories of specialized """"""""satellite"""""""" repositories, including collections of hematological and neurosurgical specimens. Future plans include increasing specimen capture to meet growing investigator needs, and expanding a new paraffin block collection.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA124435-07
Application #
8475457
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
7
Fiscal Year
2013
Total Cost
$66,921
Indirect Cost
$4
Name
Stanford University
Department
Type
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Pollom, Erqi L; Fujimoto, Dylann K; Han, Summer S et al. (2018) Newly diagnosed glioblastoma: adverse socioeconomic factors correlate with delay in radiotherapy initiation and worse overall survival. J Radiat Res 59:i11-i18
Nørgaard, Caroline Holm; Jakobsen, Lasse Hjort; Gentles, Andrew J et al. (2018) Subtype assignment of CLL based on B-cell subset associated gene signatures from normal bone marrow - A proof of concept study. PLoS One 13:e0193249
Im, Hogune; Rao, Varsha; Sridhar, Kunju et al. (2018) Distinct transcriptomic and exomic abnormalities within myelodysplastic syndrome marrow cells. Leuk Lymphoma 59:2952-2962
Huang, Min; Zhu, Li; Garcia, Jacqueline S et al. (2018) Brd4 regulates the expression of essential autophagy genes and Keap1 in AML cells. Oncotarget 9:11665-11676
Chiou, Shin-Heng; Dorsch, Madeleine; Kusch, Eva et al. (2018) Hmga2 is dispensable for pancreatic cancer development, metastasis, and therapy resistance. Sci Rep 8:14008
Breslow, David K; Hoogendoorn, Sascha; Kopp, Adam R et al. (2018) A CRISPR-based screen for Hedgehog signaling provides insights into ciliary function and ciliopathies. Nat Genet 50:460-471
Chu, Lisa W; Till, Cathee; Yang, Baiyu et al. (2018) Circadian genes and risk of prostate cancer in the prostate cancer prevention trial. Mol Carcinog 57:462-466
Patel, Manali I; Sundaram, Vandana; Desai, Manisha et al. (2018) Effect of a Lay Health Worker Intervention on Goals-of-Care Documentation and on Health Care Use, Costs, and Satisfaction Among Patients With Cancer: A Randomized Clinical Trial. JAMA Oncol 4:1359-1366
Trieu, Vanessa; Pinto, Harlan; Riess, Jonathan W et al. (2018) Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck. Oncologist 23:764-e86
Kuonen, François; Surbeck, Isabelle; Sarin, Kavita Y et al. (2018) TGF?, Fibronectin and Integrin ?5?1 Promote Invasion in Basal Cell Carcinoma. J Invest Dermatol 138:2432-2442

Showing the most recent 10 out of 322 publications